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Abstract
Background: Although currently available IGRA have been reported to be promising markers for TB infection, they cannot
distinguish active tuberculosis (TB) from latent infection (LTBI).
Objective: Children with LTBI, active TB disease or uninfected were prospectively evaluated by an in-house ELISPOT assay in
order to investigate possible immunological markers for a differential diagnosis between LTBI and active TB.
Methods: Children at risk for TB infection prospectively enrolled in our infectious disease unit were evaluated by in-house
IFN-c and IL-2 based ELISPOT assays using a panel of Mycobacterium tuberculosis antigens.
Results: Twenty-nine children were classified as uninfected, 21 as LTBI and 25 as active TB cases (including 5 definite and 20
probable cases). Significantly higher IFN-c ELISPOT responses were observed in infected vs. uninfected children for ESAT-6
(p,0.0001), CFP-10 (p,0.0001), TB 10.3 (p = 0.003), and AlaDH (p= 0.001), while differences were not significant considering
Ag85B (p = 0.063), PstS1 (p = 0.512), and HspX (16 kDa) (p = 0.139). IL-2 ELISPOT assay responses were different for ESAT-6
(p,0.0001), CFP-10 (p,0.0001), TB 10.3 (p,0.0001), HspX (16 kDa) (p,0.0001), PstS1 (p,0.0001) and AlaDH (p= 0.001); but
not for Ag85B (p = 0.063). Comparing results between children with LTBI and those with TB disease differences were
significant for IFN-c ELISPOT only for AlaDH antigen (p = 0.021) and for IL-2 ELISPOT assay for AlaDH (p,0.0001) and TB 10.3
antigen (p = 0.043). ROC analyses demonstrated sensitivity of 100% and specificity of 81% of AlaDH-IL-2 ELISPOT assay in
discriminating between latent and active TB using a cut off of 12.5 SCF per million PBMCs.
Conclusion: Our data suggest that IL-2 based ELISPOT with AlaDH antigen may be of help in discriminating children with
active from those with latent TB.
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Substantial advances have been recently achieved in the
immunological diagnosis of Mycobacterium tuberculosis infection [1].
Three Mycobacterium tuberculosis specific interferon-c (INF-c) release
assays (IGRAs) are now commercially available. With respect of
tuberculin skin test (TST), IGRAs have a number of advantages:
they are minimally influenced by previous bacille Calmette-Gue´rin
(BCG) vaccination or infection by non-tuberculosis mycobacteria,
do not cause booster effect, do not necessitate of a double access to
health care facility, and interpretation of results is not operator-
dependent [2]. In adults IGRAs have been reported to be more
specific and at least as sensitive as TST [3], and are currently
included in diagnostic algorithms in adult guidelines [4]. However,
reported IGRAs sensitivity and specificity largely vary among
studies in paediatric populations and caution is recommended
regarding their use in children [1,5,6,7]. Moreover, IGRAs do not
distinguish LTBI from active tuberculosis (TB) patients [8]. This
issue is fundamental for paediatricians since a definite diagnosis of
active TB is rare in children. Paediatric TB disease is typically
paucibacillary and most TB diagnoses are ‘‘probable ‘‘diseases,
based on TST/IGRA results, clinical symptoms and signs,
radiological findings, epidemiological data, and response to
antitubercular therapy [1,5–8]. Therefore a test able to distinguish
accurately LTBI from active TB would be valuable. IGRAs based
on cytokines other than IFN- c or exploring immune response to
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other mycobacterial antigens besides those included in the
commercially available IGRAs are currently under investigations
[8].
Previous observations suggest a possible role of IL-2- based
ELISPOT assay in addition to the IFN-gamma-based assay in
discriminating active from latent TB, as only cells from individuals
with LTBI and not those from individuals with active TB has been
found to secrete IL-2 after specific stimulation [9]. These results
probably reflect the increased number of IL-2 secreting and IL-2/
IFN-gamma secreting central memory T cells and the reduced
number of IFN-gamma effector T-cells in LTBI patients,
associated with the low bacterial replication and low antigen load
[10]. In the present study we prospectively evaluated the
performances of in-house IFN-c and IL-2 based ELISPOT assays
by the use of a panel of Mycobacterium tuberculosis antigens in
children consecutively referred to one paediatric infectious disease
unit and at risk for TB infection with the aim of investigating
possible immunological markers for a differential diagnosis
between LTBI and active TB.
Materials and Methods
Study subjects
Children at risk for TB infection consecutively referred to our
Infectious Disease Unit were prospectively enrolled between 1 st
January 2009 and 31st April 2010. Study children were those with
clinical suspicion of TB disease and/or in close contact with
recently diagnosed cases of contagious TB disease and/or
internationally adopted or recently immigrated children coming
from countries with a high-prevalence of TB. Children with
congenital or acquired immunodeficiency disorders (based on their
medical history, clinical examination and/or laboratory tests) were
excluded from the study. This study was approved by the ethical
committee of the Anna Meyer University Hospital, Florence, Italy.
All the parents/tutors of the study children gave written consent to
the study.
Tuberculin skin test (TST)
TST was administered by trained nurses dedicated to our
Infectious Disease Unit and was performed according to the
Mantoux method by injecting intradermally 5 tuberculin units (in
0.1 mL) of purified protein derivative (Statens Serum Institute,
Copenhagen, Denmark) into the volar surface of the forearm. The
transversed skin induration was recorded (in mm) after 48–
72 hours directly by a pediatrician of the Infectious Disease Unit.
Following the American Academy of Pediatrics guidelines [7], a
positive TST was defined as an induration size $5 mm for
children in close contact with known or suspected contagious case
of TB disease or for children suspected to have TB disease (based
on clinical evidence and/or chest radiograph) and $10 mm for
children born in countries with a high prevalence of TB and
recently immigrated.
QuantiFERON Gold In tube test (QFT-G-IT)
The QFT-IT assay (Cellestis Inc., Australia) was performed
according to the manufacturer’s instructions as described previ-
ously. After subtracting the value from the negative control, the
result was positive if, the antigen-dependent response was
$0.35 IU, negative if the mitogen–induced response was
$0.5 IU/mL and the antigen-dependent response was
,0.35 IU/mL, and indeterminate if both mitogen-induced and
antigen-dependent responses were below cut-off or mitogen-
induced response .8 IU/mL.
ELISPOT Assay
In-house ELIPOT assay detecting IFN-gamma and IL-2
responses were performed using recombinant M. tuberculosis
antigens (ESAT-6, CFP-10, TB 10.3, AlaDH, Ag85B, PstS1,
HspX (16 kDa) protein), provided by Lionex Diagnostics &
Therapeutics GmbH (Braunschweig, Germany), as previously
reported [10,11]. Characteristics of the used antigens are
summarized in Table 1. Briefly, peripheral blood mononuclear
cells (PBMCs; 16106 cells/mL) of each patients were stimulated
with M. tuberculosis recombinant antigen (5 mg/mL), and seeded in
triplicate in 96-well plates coated with anti–IFN-c or anti–IL-2
antibody. Cells stimulated with medium alone served as negative
controls. Cells stimulated with phytohemoagglutinin (PHA) served
as positive controls. IFN-c and IL-2 ELISPOT microplates were
then incubated at 37uC in 5% CO2 for 24 hours. At the end of the
culture period, plates were washed and incubated for 3 hours with
the appropriate biotinylated anti–IFN-c or anti–IL-2 monoclonal
antibody. Streptavidin-HRP complex was then added for 2 hours,
followed by the substrate solution. Spot forming colonies (SFCs)
were counted using an automated ELISPOT reader (Autoimmune
Diagnostika GmbH) and results expressed as number of SFCs per
million PBMCs, as described [12]. Laboratory workers were blind
to the clinical status of participants.
Study design
Information regarding demographic data, prior TB exposure,
and past medical history was obtained from each child’s parents or
tutors or from medical documentation and recorded into the study
database. Children were considered vaccinated with BCG whether
a clear documentation was available and/or a scar was present. All
children underwent clinical evaluation, TST and venipuncture for
IGRAs (QFT-G-IT and in-house ELISPOT assay) and results
entered into a databse. Blood was taken during the first
examination after the parent’s or tutor’s informed consent had
been obtained and before starting any anti-tubercular treatment.
Chest radiography was performed in all symptomatic children, in
those with a positive TST, and in all contacts aged less than 5
years [7]. Children with suspected pulmonary TB had three
sputum or early morning gastric aspirates samples collected for
Mycobacterium tuberculosis detection (by means of microscopy,
polymerase chain reaction and culture) [7]. Chest computed
tomography (CT) scan was performed in selected cases at the
paediatrician’s discretion. No suspected or ascertained extra-
pulmonary TB cases presented at the Infectious Disease Unit
during the study period.
The study received approval from the Ethical Committee of
Anna Meyer Children University Hospital.
Definition of study groups
Study children were classified as not-infected, LTBI cases, or
active TB disease cases, following the American Academy
Guidelines definition [7]. In the event of discordant TST/QFT-
G-IT results, children were assigned to the corresponding group
on the bases on the TST result [7]. In particular, asymptomatic
children with negative TST were defined as uninfected. LTBI
diagnosis was assigned to any child with a positive TST and no
clinical or radiographic evidence of active TB [7]. Cases of active
TB were defined according to two categories: 1) definite TB,
children with Mycobacterium tuberculosis cultured or detected by
microscopy or molecular methods from sputum or gastric aspirate
culture; 2) probable TB: absence of microbiological confirmation
but presence of all of the following criteria: (A) clinical symptoms
and signs of active TB, (B) abnormal radiography and/or CT scan
consistent with lung TB, (C) response to TB therapy plus, (D)
ELISPOT in Children at Risk for Tuberculosis
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either a history of TB contact or travel to a TB-endemic country
within the last 24 months [13]. No suspected or ascertained extra-
pulmonary TB cases presented at the Infectious Disease Unit
during the study period.
Statistical Analysis
Categorical data were compared using the Chi-squared test (or
Fisher’s exact test, when expected cell sizes were smaller than five).
The Wilcoxon-Mann-Whitney test was used for continuous
measurements to test relationships in unpaired analysis, when
assumed that the dependent variable is a not normally distributed
interval variable. Test concordance was assessed by Cohen’s k-
statistics with agreement considered slight’for k#0.2, ‘fair’ for
0.2,k#0.4, ‘moderate’for 0.4,k#0.6, ‘substantial’for 0.6,k#0.8
and ‘optimal’for 0.8,k#1.0. Receiver operating characteristic
(ROC) curve analysis was conducted to determine the best IL-2
and IFN-c ELISPOT result thresholds in discriminating between
children with active or latent TB, relatively to a specific M.
tuberculosis antigen, and correspondent sensitivity and specificity
were reported. The area under the ROC curve (AUC) and 95%
confidence interval (CI) were also calculated. Statistical analysis
was performed using the statistical software SPSS for Windows,
version 14.0. P,0.05 was considered statistically significant.
Results
Seventy five children were included in the study. Twenty-none
children were classified as uninfected, 21 as LTBI and 25 as active
TB cases (including 5 definite and 20 probable cases). Character-
istics of the study children are summarized in Table 2.
Discordant TST/QFT-G-IT result was obtained in four
children (one child with definite TB, positive QFT-G-IT and
negative TST and three children with probable TB, negative
QFT-G-IT and positive TST). The overall agreement between
QFT-G-IT and the TST was substantial with a k value of 0.679.
IFN-c and IL-2 ELISpot results
ELISPOT assay results are summarized in Table 3. Signifi-
cantly higher median values were evidenced in infected vs.
uninfected children considering IFN-c ELISPOT responses to
ESAT-6 (p,0.0001), CFP-10 (p,0.0001), TB 10.3 (p = 0.003),
and AlaDH (p= 0.001), while differences were not significant
considering Ag85B (p = 0.063), PstS1 (p= 0.512), and HspX
(16 kDa) protein (p = 0.139). Considering IL-2 ELISPOT results
significantly different responses were evidenced for ESAT-6
(p,0.0001), CFP-10 (p,0.0001), TB 10.3 (p,0.0001), HspX
(16 kDa) (p,0.0001), PstS1 (p,0.0001) and AlaDH (p= 0.001);
but not for Ag85B (p= 0.063). Comparing results between
children with LTBI and those with TB disease (probable plus
definite disease) differences were significant for IFN-c ELISPOTt
only for AlaDH antigen (p = 0.021) (Table 3). With regard to IL-2
ELISPOT assay, significant differences were observed for AlaDH
(p,0.0001) and TB 10.3 antigen (p = 0.043), while no difference
was evidenced considering other antigens. ROC analyses demon-
strated sensitivity of 100% and specificity of 81%, in discriminat-
ing between latent and active TB, considering response to AlaDH
by IL-2 ELISPOT assay for a cut off of 12.5 SCF per million
PBMCs. For IFN-c ELISPOT assay the performance was much
poorer: for the best threshold of 42.0 SCF per million PBMCs
sensitivity was 88% and specificity 56% (Figure 1).
Discussion
In the present study we evaluated the performances of IFN-c
and IL-2 based ELISPOT assays in children at risk for TB using
an array of M. tuberculosis specific antigens. We observed
significantly different responses between infected and not-infected
children with respect to antigens included in the commercially
available IGRAs (ESAT-6 and CFP-10), as well as to other
mycobacterial antigens (TB 10.3, AlaDH for IFN-gamma and IL-
2; HspX and PstS1 only for IL-2 based ELISPOT), but not for
Ag86B. This latter result was in contrast to what we expected,
Table 1. Characteristics of the used antigens: all the used antigens were recombinant proteins (from Hoghart et al. [14], modified).
Protein Gene Bank Accession number Remarks Putative function
ESAT-6 Rv3875 6 kDa early secreted antigen Unknown
CFP-10 Rv3874 10 kDa culture filtrate antigen of M.
tuberculosis
Unknown
Ag85B Rv1886c Secreted antigen, member of the
immunodominant complex Antigen
85
Cell wall synthesis, fibronectin
binding




TB10.3 Rv3019c Secreted ESAT6-like protein Unknown
HspX (16 kDa;Acr) Rv2031c Heat shock protein. It has been
identified as a major protein
expressed in dormant state
Stress protein induced by anoxia. It has a
role in manteinance of long-term viability
during latent asymptomatic infection and a
proposed role in replication during initial
infection
AlaDH Rv2780 Secreted L-alanine deydrogenase of
M. tuberculosis
May play a role in cell wall synthesis
(as L-alanine in an important
constituent of the peptidoglycan layer) ;
crystal structure varies in the phase of
active disease with respect to the state of
latent infection in ‘‘open’’ and ‘‘closed’’
ternary forms
doi:10.1371/journal.pone.0046041.t001
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considering that Ag85B has been described to elicit a robust
immune response in TB patients and it is a candidate protein to be
included in new antitubercular vaccines [14]. Indeed Ag85B is one
of the most dominant protein antigens secreted from all
mycobacteria species, showing extensive cross-reactivity between
different species [15]. Thus, exposure to enviromental mycobac-
teria might sustain an immune response to this antigen in children
not-infected by M. tuberculosis.
No difference in responses to ESAT-6, CFP-10 and other
mycobacterial antigens (Ag85B, PstS1, HpsX) was found between
children with latent and active tuberculosis, while significant
differences were found in responses to TB 10.3 and AlaDH
antigens. TB 10.3 is a member of the large 23 protein ESAT-6
gene family and contains several unique T-cell epitopes strongly
recognised by TB patients [13]. The recognition of a number of
unique epitopes on TB10.3 suggests that this protein is highly
Table 2. Characteristic of the 75 study children, according to their final diagnosis.
Uninfected Latent TB Probable TB disease Definite TB disease
n=29 n=21 n=20 n=5
n (%) n (%) n (%) n (%)
Age, months (median and IQR) 77 (28–101) 86 (61–101) 52(27–82) 47 (8–97)
Immigrated 21 (72.4) 15 (71.4) 18 (90) 4 (80.0)
BCG vaccinated 5 (17.2) 7 (33.3) 1 (5.0) 0 (0.0)
TST (mm)
,5 28 (96.5) 0 (0.0) 0 (0.0) 1 (20.0)
$5 and ,10 1 (3.5) 1 (4.8) 2 (10.0) 0 (0.0)
$10 and ,15 0 (0.0) 5 (23.1) 1 (5.0) 1 (20.0)
$15 0 (0.0) 15 (71.5) 17 (85.0) 3 (60.0)
QFT-G-IT result
negative 29 (100.0) 5 (23.1) 3 (15.0) 5 (100.0)
positive 0 (0.0) 15 (71.5) 17 (85.0) 0 (0.0)
indeterminate 0 (0.0) 1 (4.8) 0 (0.0) 0 (0.0)
Note. TB: tuberculosis; BCG: Bacille Calmette-Gue´rin vaccine; TST = tuberculin skin test; QFT-G-IT: QuantiFERON-Gold In Tube test.
doi:10.1371/journal.pone.0046041.t002






(n=29) (n=21) n=20 n=5
Uninfected vs.
infected children Latent vs. overt disease
IFN-c ELISpot result*
- ESAT-6 35 (1–102) 320 (157–520) 292 (170–631) 330 (190–1575) ,0.0001 0.724
- CFP-10 40 (1–120) 305 (130–625) 280 (76–986) 875 (200–3532) ,0.0001 0.691
- Ag85B 65 (12–152) 150 (47–322) 107 (46–192) 90 (27–1517) 0.063 0.724
- TB 10.3 100 (27–292) 270 (135–465) 252 (80–395) 570 (225–1742) 0.003 0.487
- AlaDH 35 (12.5–110) 85 (17–180) 147 (71–303) 280 (115–1565) ,0.001 0.021
- PstS1 40 (1–122) 50 (1–197) 60 (11–241) 95 (18–982) 0.0512 0.504
- HspX - 16KD 10 (1–162) 85 (1–300) 42 (1–307) 40 (13–1345) 0.139 0.720
IL-2 ELISpot result*
- ESAT-6 10 (1–35) 220 (35–410) 110 (60–402) 420 (155–1365) ,0.0001 0.791
- CFP-10 10 (1–20) 210 (85–710) 160 (100–637) 510 (355–1735) ,0.0001 0.574
- Ag85B 20 (10–75) 40 (10–140) 45 (17–195) 200 (135–1485) 0.063 0.188
- TB 10.3 1 (1–30) 50 (12.5–210) 130 (52–402) 390 (220–1695) ,0.0001 0.043
- AlaDH 1 (1–20) 1 (1–10) 75 (36–130) 340 (110–1365) 0.001 ,0.0001
- PstS1 10 (1–50) 20 (1–75) 20 (10–95) 10 (5–155) ,0.0001 0.755
- HspX- 16 KD 1 (1–10) 60 (20–280) 45 (1–155) 240 (45–920) ,0.0001 0.626
Note.
*Results are expressed as median and interquartile range of spot forming colonies per million PBMCs; TB:tuberculosis.
doi:10.1371/journal.pone.0046041.t003
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expressed by the bacteria during active TB infection, potentially
explaining our finding [16]. To our knowledge this is the first
report on a potential role of TB 10.3 to differentiate between LTBI
and active TB, deserving further investigations.
Considering AlaDH antigen, the differences observed in
children with LTBI and active TB may have a biological
explanation. Differently from the other antigens included in our
study, AlaDH is the only whose conformation is modified in latent
with respect to active TB [17]. It has been demonstrated that
AlaDH shows altered expression profile upon adaptation to
dormancy: a condition that may be related to the state of latent
infection. Though an obligatory aerobic organism, M. tuberculosis is
able to adapt to and survive in the hypoxic and hostile
environment of host macrophages undergoing a dramatic change
in gene transcription during a latent infection [8]. AlaDH is an
enzyme involved in nitrogen metabolism and has been implicated
in the adaptation of mycobacteria to the anaerobic dormant state.
The crystal structure varies in the phase of active disease with
respect to the state of latent infection in ‘‘open’’ and ‘‘closed’’
ternary forms, thus explaining a possible different host immune
response according to the infectious status [17]. We observed that
different responses between children with LTBI and active TB
were more pronounced with the IL-2 based than with the IFN-c
based ELISPOT. ROC analyses demonstrated that, for a cut off of
12,5 SCF per million PBMC, the sensitivity in discriminating
children with LTBI and active TB reached 100% while specificity
was 81% by the use of IL-2 based ELISpot assay. The
performance of the IFN-c ELISpot assay was poor, especially
due to its low specificity. These findings suggest that IL-2 based
ELISPOT assay with AlaDH antigen may be of help in
discriminating children with active from those with latent TB.
The finding that the differences in response to AlaDH were more
pronounced considering IL-2 instead of IFN-c based ELISPOT
assays are not clearly explainable. In contrast with our findings, in
adults studies, ESAT-6 and CFP-10 IFN-c ELISPOT assays were
more likely to be positive in recently infected patients, while IL-2 a
positive ELISPOT was related to ancient exposure, since this test
better explores the central memory T-cell response [9,18]. A
higher production of IL-2 in latently infected people after 72 h
incubation has been documented. Thus a prolonged incubation
period seems to be essential to reveal increased number of central
memory T-cells in LTBI adults [9]. However, it should be
remembered that the TH1 response may be immature and
peculiar in children. In this population IL-2 based IGRAs have
been reported to show higher performance than IFN-c based
assays, explaining, at least partially, our results [19]. Further
pediatric studies prolonging the culture up to 3 days could provide
further information in children. Further pediatric studies prolong-
ing the culture up to 3 days could provide further information in
children. We did not observe any difference between children with
active or latent diseases when exploring response to HspX
(16 kDa) antigen. This antigen has been depicted as one of the
most prominent latency proteins [20], and a strong response to
HspX, largely restricted to latently infected individuals, has been
previously reported by Demissie and colleagues in adults [20].
Discrepancies between our and previous findings at this regard
may be due to the limited datasets, or to actual differences in the
immune response between adult and paediatric populations.
Figure 1. A receiver operator characteristic (ROC) plot is shown, illustrating sensitivity and specificity of AlaDH IFN-c and IL-2
ELISpot results in discriminating children with latent (n=21) and overt (n=25) tuberculosis. Area under the ROC curve was 0.700 (95%IC:
0.547-0.853; p = 0.021 vs. the identity - diagonal - line) considering IFN-c ELISpot and 0,896 (95%IC: 0.785–1.008; p,0.0001 vs. the identity - diagonal -
line) for IL-2 ELISPOT.
doi:10.1371/journal.pone.0046041.g001
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Our study has several limitations. Definition of study groups was
based on TST results and not on QFT-G-IT results according to
the most recent US guidelines in children [7]. However, children
could have been classified according to their QFT-G-IT instead of
TST results and three of our study children with discordant
TST+/QFT-G-IT would have assigned to a different group. We
repeated the analyses after excluding these children and results
were substantially unchanged. Moreover, similarly to the majority
of paediatric studies most of the overt TB cases were probable and
not definite diseases and in general our dataset is small. Thus even
if intriguing, our findings should be confirmed in larger paediatric
populations.
Conclusion
Our data suggest that IL-2 and IFN-gamma based ELISPOT
with AlaDH antigen may be of help in discriminating children
with active from those with latent TB.
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